Project Grant HT94252310432
Award Date
7/1/23
Completion Date
6/30/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
The University of Minnesota was awarded a $479,946 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,848,000.00 to the Regents of the University of Minnesota to conduct research on therapeutic targeting of aberrant mRNA polyadenylation in lethal prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in this critical medical domain. The...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
The federal Project Grant award of $1,059,132 from the Military Medical Research and Development program (CFDA 12.420) of the Defense Health Agency supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The award to the Regents of the University of Minnesota will fund a research project titled "NATURAL KILLER CELL-MEDIATED TARGETING OF IGF1R AND IR-A IN HORMONE RECEPTOR-POSITIVE BREAST CANCER" over the period of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,618,500.00 to the Regents of the University of Minnesota to support research aimed at "Targeting eIF4F Complex-Driven Translation of Oncogenic mRNAs in CRPC". The 3-year award, which runs from June 1, 2025 to May 31, 2028, will fund advanced biomedical research focused on innovative solutions to transform healthcare for military service...
The University of Minnesota was awarded a three-year, $556,454 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to define the relative contributions of K27 methylation and S31 phosphorylation to gliomagenesis in diffuse intrinsic pontine glioma (DIPG). Through September 2022 to August 2025, University researchers will investigate medical solutions for brain tumors on the...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $783,191.00 to the Regents of the University of Minnesota to conduct in vivo gene therapy research for Fanconi anemia. The award period runs from September 1, 2025 to August 31, 2028. As a prominent land-grant research institution, the University of Minnesota leverages its extensive academic capabilities to support the program's objectives of...